Entero Healthcare Solutions Ltd (ENTERO) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Entero Healthcare Solutions reported strong growth and consistent execution in Q3 FY25.
- Consolidated revenue reached INR1,359 crores, a 37% YoY increase, with 17% organic growth, outpacing the Indian Pharmaceutical Market (IPM) growth of 7%.
- Gross profit increased by 48% YoY to INR133 crores, with gross margin improving to 9.8% from 9.1% in Q3 FY24.
- EBITDA grew by 75% YoY to INR50 crores, with EBITDA margin expanding to 3.7% from 2.9% in Q3 FY24.
- Completed 10 acquisitions in FY25, contributing INR792 crores in annualized revenue, expanding presence in new geographies and product categories.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.